Peptide Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2030

Peptide Therapeutics Market By Drug Type (Branded And Generic), Application (Gastrointestinal Disorders, Metabolic Disorders, Cancer, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing number of people with cancer and increasing research and development activities

The global peptide therapeutics market was estimated to grow at a CAGR of 9.79% during the forecast period from 2024 to 2030. The demand for Peptide Therapeutics is primarily being boosted by the rising burden of cancer and other metabolic disorders such as diabetes, obesity, and others. Furthermore, the peptide therapeutics market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the peptide therapeutics market during the forecast period from 2024-2030.

Peptide Therapeutics Market Dynamics:

The study conducted by the International Agency for Research on Cancer mentioned that worldwide, an estimated 19.3 million new cancer cases were reported in 2020.

According to the data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.

Also, as per Global Cancer Observatory 2021 data, globally around 544,352 cases of non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. As per the same source globally around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020.

The data published by Global Cancer Observatory (2020) says that globally around 1.41 million new cases of prostate cancer were reported in 2020 and by 2040 this number is expected to reach 2.24 million.

Peptide therapeutics are considered a promising and innovative approach for the treatment of different cancer types. For example, Plenaxis (abarelix) is intended for the treatment of advanced-stage prostate cancer.

In addition, the data published by the International Diabetes Federation 2021 stated that around 537 million adults aged between 20 and 79 years were suffering from diabetes in 2021.

According to the World Obesity Federation 2022, it has been predicted that by 2030 about 1 billion people around the world, including 1 in 5 women and 1 in 7 men, will be living with obesity.

Therefore, the increasing patient population suffering from cancer, diabetes, and other diseases globally is thereby anticipated to propel the overall growth of the peptide therapeutics market during the forecast period from 2024-2030.

However, challenges associated with the discovery and development of peptide therapeutics and side-effects associated with peptide therapy may restrict the growth of the overall peptide therapeutics market.

Peptide Therapeutics Market Segment Analysis:

Peptide Therapeutics Market by Drug Type (Branded and Generic), Application (Gastrointestinal Disorders, Metabolic Disorders, Cancer, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the application segment of the peptide therapeutics market, the gastrointestinal disorders category is expected to amass a significant revenue share in the year 2023.

The rising incidence of various gastrointestinal disorders such as Crohn's disease, ulcerative colitis, diverticulitis, malabsorption, short bowel syndrome, and Gastroesophageal reflux disease (GERD) among others is likely to increase the demand for peptide therapeutics available for their treatment.

For instance, according to the European Federation of Crohn's and Ulcerative Colitis Associations 2022, worldwide around 10 million people are suffering from inflammatory bowel disease.

As per Crohn's & Colitis Australia 2022, it was estimated that around 100,000 to 160,000 people were living with Crohn's disease and Ulcerative Colitis in Australia in 2022, thus adding to the global disease burden of IBD.

As per the Centers for Disease Control and Prevention 2022, about 3 million people are living with IBD in the United States. As per the same source, around 80,000 children are expected to be suffering from IBD in the US.

Peptide therapeutics are crucial for the treatment and management of patients suffering from various gastrointestinal disorders. For example, Teduglutide is intended for the treatment of short bowel syndrome in people who need additional nutrition or fluids from intravenous (IV) therapy.

Similarly, another peptide therapeutic Linaclotide is indicated for the treatment of irritable bowel syndrome (IBS) with constipation and chronic idiopathic constipation
Thus, all the above mentioned factors are likely to propel the segmental market for peptide therapeutics.

North America is expected to dominate the overall Peptide Therapeutics Market:

Among all the regions, North America is estimated to account for the largest share of the Peptide Therapeutics Market in the year 2023. The market growth is due to various crucial factors, such as increased awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the developing biotechnology industry. In addition, the rising prevalence of various chronic diseases such as cancer, diabetes, and others is also going to accelerate the regional market growth.

As per the figures mentioned by the American Cancer Society 2021, it was estimated that around 1.9 million new cancer cases were diagnosed in the United States in 2021. Also, according to the data provided by the Centers for Disease Control and Prevention (CDC) in 2021, around 1,752,735 new cases of cancer were reported in the US in 2019.

According to the National Cancer Institute 2020, it was estimated that around 1,806,590 cancer cases were diagnosed in the year 2020 in the United States. Also, as per the same source prostate, lung, and colorectal cancer accounts for 43% of the cancer cases in men, and breast, lung, and colorectal make up 50% of cancer cases in women.

As per the Centers for Disease Control and Prevention (CDC) 2021, around 28.7 million people in the US had diabetes in the year 2019. Moreover, as per the Centers for Disease Control and Prevention 2022 data, around 96 million people had prediabetic conditions in the year 2019 in the US.

Also, the rising number of approvals for peptide therapeutics in the region is likely to boost the market. For example, in May 2019, the US Food and Drug Administration (FDA) approved GATTEX® (teduglutide) for children 1 Year of age and older with short bowel syndrome (SBS).

Thus, all the above mentioned factors are likely to increase the market for peptide therapeutics in the region during the forthcoming years.

Peptide Therapeutics Market Key Players:

Some of the key market players operating in the peptide therapeutics market include AbbVie Inc., AstraZeneca, Lilly, GSK, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Astellas Pharma Inc., Shire plc, Ferring B.V., Rhythm Pharmaceuticals, Novo Nordisk A/S, Ironwood, Amgen Inc., F. Hoffmann-La Roche Ltd., and Others.

Recent Developmental Activities in the Peptide Therapeutics Market:

• In March 2023, Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration agreement with PeptiDream Inc., to discover and develop novel macrocyclic constrained peptide drugs against multiple targets of Ono's interest.
• In December 2023, Ambio, Inc., an innovative biotech company developing novel peptide drugs, biosimilar, bioequivalent, and other complex generic drugs, announced that a generic version of Forteo®1 (teriparatide injection) developed by Ambio and to be marketed and sold by Apotex has been approved by the US Food and Drug Administration (FDA).

Key Takeaways from the Peptide Therapeutics Market Report Study

• Market size analysis for current peptide therapeutics market size (2023), and market forecast for 6 years (2024-2030)
• Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global peptide therapeutics market.
• Various opportunities available for the other competitors in the peptide therapeutics market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current peptide therapeutics market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for peptide therapeutics market growth in the coming future?

Target Audience who can be benefited from this Peptide Therapeutics Market Report Study

• Peptide Therapeutics product providers
• Research organizations and consulting companies
• Peptide Therapeutics-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in peptide therapeutics
• Various End-users who want to know more about the peptide therapeutics market and the latest developments in the peptide therapeutics market.

Frequently Asked Questions for the Peptide Therapeutics Market:

1. What are peptide therapeutics?

Peptide Therapeutics are peptides or polypeptides meant for the treatment and management of various diseases and conditions including cancer, diabetes, and others.

2. What is the market for global peptide therapeutics?

The global peptide therapeutics market was estimated to grow at a CAGR of 9.79% during the forecast period from 2024 to 2030.

3. What are the drivers for the global peptide therapeutics market?

The demand for peptide therapeutics is primarily being boosted by the rising burden of cancer and other metabolic disorders such as diabetes, obesity, and others. Furthermore, the peptide therapeutics market is anticipated to grow on account of a large number of ongoing research activities in this field, collaborations between healthcare providers, researchers, and industry players, and strategic partnerships among others are going to contribute to the overall growth of the peptide therapeutics market during the forecast period from 2024-2030.

4. Who are the key players operating in the global peptide therapeutics market?

Some of the key market players operating in the peptide therapeutics market include AbbVie Inc., AstraZeneca, Lilly, GSK, Takeda Pharmaceutical Company Limited, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Astellas Pharma Inc., Shire plc, Ferring B.V., Rhythm Pharmaceuticals, Novo Nordisk A/S, Ironwood, Amgen Inc., F. Hoffmann-La Roche Ltd., and Others.

5. Which region has the highest share in the peptide therapeutics market?

North America is expected to dominate the overall peptide therapeutics market during the forecast period from 2024-2030. The market growth is due to various crucial factors, such as increased awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the developing biotechnology industry. In addition, the rising prevalence of various chronic diseases such as cancer, diabetes, and others is also going to accelerate the regional market growth.


This product will be delivered within 3-5 business days.